Kymera Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent prot...
Latest News
18 days ago · seekingalpha.com
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call TranscriptKymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
19 days ago · marketbeat.com
Kymera Therapeutics Q3 Earnings Call HighlightsKymera Therapeutics NASDAQ: KYMR reported third-quarter results and outlined progress across its clinical pipeline, including phase I healthy-volunteer data for KT-579, an oral degrader targeting IRF5 for autoimmune diseases. The company also said it expects to report phase IIb data for its STAT6 degrader, KT-621, in atopic dermatitis by year-end.
19 days ago · globenewswire.com
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer TrialKT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile
19 days ago · globenewswire.com
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-579 in healthy volunteers on Thursday, October 29, 2026, as part of its previously scheduled third quarter 2026 financial results. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
25 days ago · globenewswire.com
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
29 days ago · zacks.com
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
2 months ago · seekingalpha.com
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptKymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · seekingalpha.com
Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptKymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
2 months ago · zacks.com
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock?
2 months ago · zacks.com
Can KT-621 Mark a Turning Point for Kymera Therapeutics?KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove KYMR